IN2014DN07384A - - Google Patents

Info

Publication number
IN2014DN07384A
IN2014DN07384A IN7384DEN2014A IN2014DN07384A IN 2014DN07384 A IN2014DN07384 A IN 2014DN07384A IN 7384DEN2014 A IN7384DEN2014 A IN 7384DEN2014A IN 2014DN07384 A IN2014DN07384 A IN 2014DN07384A
Authority
IN
India
Prior art keywords
compounds
disclosed
mediated
pyrimidinebased
pyrazolo
Prior art date
Application number
Other languages
English (en)
Inventor
Yingzhi Bi
Kenneth Gordon Carson
Giovanni Cianchetta
Michael Alan Green
Godwin Kumi
Alan Main
Yulian Zhang
Glenn Gregory Zipp
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of IN2014DN07384A publication Critical patent/IN2014DN07384A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN7384DEN2014 2012-03-09 2013-03-05 IN2014DN07384A (h)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261608765P 2012-03-09 2012-03-09
PCT/US2013/029056 WO2013134228A1 (en) 2012-03-09 2013-03-05 PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE

Publications (1)

Publication Number Publication Date
IN2014DN07384A true IN2014DN07384A (h) 2015-04-24

Family

ID=47892052

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7384DEN2014 IN2014DN07384A (h) 2012-03-09 2013-03-05

Country Status (25)

Country Link
US (3) US8946415B2 (h)
EP (1) EP2834243B1 (h)
JP (1) JP6418950B2 (h)
KR (1) KR101965025B1 (h)
CN (1) CN104302649B (h)
AR (1) AR090292A1 (h)
AU (1) AU2013230128B2 (h)
BR (1) BR112014022000A8 (h)
CA (1) CA2866143C (h)
DK (1) DK2834243T3 (h)
ES (1) ES2676224T3 (h)
HU (1) HUE038786T2 (h)
IL (1) IL234486A (h)
IN (1) IN2014DN07384A (h)
MX (2) MX345830B (h)
NZ (1) NZ630721A (h)
PL (1) PL2834243T3 (h)
PT (1) PT2834243T (h)
RU (1) RU2014140735A (h)
SG (1) SG11201405561RA (h)
TR (1) TR201808280T4 (h)
TW (1) TW201341386A (h)
UY (1) UY34668A (h)
WO (1) WO2013134228A1 (h)
ZA (1) ZA201406149B (h)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013134219A1 (en) 2012-03-09 2013-09-12 Lexicon Pharmaceuticals, Inc. Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
AU2013230128B2 (en) 2012-03-09 2017-08-17 Lexicon Pharmaceuticals, Inc. Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
US9708337B2 (en) 2013-02-22 2017-07-18 Bristol-Myers Squibb Company Aryl amide-based kinase inhibitors
TW201542550A (zh) 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法
ES2678877T3 (es) 2013-10-11 2018-08-20 Bristol-Myers Squibb Company Inhibidores de pirrolotriazina quinasa
ES2933350T3 (es) 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
MX2016009352A (es) * 2014-01-31 2016-10-13 Bristol Myers Squibb Co Inhibidores de quinasa a base de quinolina.
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶1之抑制劑、包含其之組成物、及其使用方法
EP3200797A1 (en) * 2014-09-30 2017-08-09 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
RU2708674C2 (ru) * 2014-12-15 2019-12-11 СиЭмДжи ФАРМАСЬЮТИКАЛ КО., ЛТД. Конденсированные кольцевые гетероарильные соединения и их применение в качестве ингибиторов trk
WO2016164295A2 (en) 2015-04-10 2016-10-13 Bristol-Myers Squibb Company Fused pyridines as kinase inhibitors
RU2732405C2 (ru) 2015-07-02 2020-09-16 Тёрнинг Поинт Терапьютикс, Инк. Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ
US10294242B2 (en) 2015-07-06 2019-05-21 Tp Therapeutics, Inc. Diaryl macrocycle polymorph
PT3733187T (pt) 2015-07-21 2024-11-08 Turning Point Therapeutics Inc Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro
US10947239B2 (en) * 2015-11-02 2021-03-16 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
CA3031100A1 (en) 2016-07-28 2018-02-01 Tp Therapeutics, Inc. Macrocycle kinase inhibitors
MX390505B (es) 2016-11-02 2025-03-20 Janssen Pharmaceutica Nv Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2
CA3041412A1 (en) 2016-11-02 2018-05-11 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
US11053248B2 (en) 2016-11-02 2021-07-06 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
JP7224334B2 (ja) 2017-07-28 2023-02-17 ターニング・ポイント・セラピューティクス・インコーポレイテッド 大環式化合物およびその使用
KR20240153614A (ko) 2017-07-28 2024-10-23 다케다 야쿠힌 고교 가부시키가이샤 Tyk2 억제제 및 이의 용도
US11230546B2 (en) * 2017-12-15 2022-01-25 Pyramid Biosciences, Inc 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer
SI3728271T1 (sl) 2017-12-19 2023-01-31 Turning Point Therapeutics, Inc. Makrociklične spojine za zdravljenje bolezni
CN109456331B (zh) * 2017-12-22 2020-06-05 深圳市塔吉瑞生物医药有限公司 一种取代的吡唑并[1,5-a]嘧啶化合物及其药物组合物及用途
CN111848622A (zh) 2018-01-23 2020-10-30 深圳市塔吉瑞生物医药有限公司 取代的吡唑并[1,5-a]嘧啶类的大环化合物
CN112771047A (zh) * 2018-09-27 2021-05-07 重庆复创医药研究有限公司 作为RET激酶抑制剂的取代的咪唑[1,2-a]吡啶和[1,2,4]三唑[1,5-a]吡啶化合物
CA3115088A1 (en) * 2018-10-15 2020-04-23 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2021216454A1 (en) * 2020-04-21 2021-10-28 Lexicon Pharmaceuticals, Inc. 4-(3-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)piperazine for use in the the treatment of cov-229e or cov-oc43 coronaviruses infections
JP2023522688A (ja) 2020-04-21 2023-05-31 レクシコン ファーマシューティカルズ インコーポレイテッド ウイルス感染症の治療に使用されるaak1阻害剤
US11478733B2 (en) 2020-11-24 2022-10-25 Caterpillar Inc. Filter interlock with tabs mating with a pedestal or a housing
TW202525819A (zh) * 2023-09-08 2025-07-01 加拿大商薩泰洛斯生物科學公司 Ap2相關激酶1抑制劑及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
JP4847275B2 (ja) * 2005-10-21 2011-12-28 田辺三菱製薬株式会社 ピラゾロ[1,5−a]ピリミジン化合物
MX2009003185A (es) 2006-09-29 2009-04-03 Novartis Ag Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
US20120058997A1 (en) * 2006-11-06 2012-03-08 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2009140128A2 (en) * 2008-05-13 2009-11-19 Irm Llc Compounds and compositions as kinase inhibitors
CA2741313C (en) * 2008-10-22 2018-12-04 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
TW201113286A (en) 2009-09-03 2011-04-16 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
EP2523552B1 (en) 2010-01-14 2015-05-13 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidines as mark inhibitors
PT3409278T (pt) * 2011-07-21 2020-12-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de proteína cinase heterocíclicos
WO2013134219A1 (en) 2012-03-09 2013-09-12 Lexicon Pharmaceuticals, Inc. Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
EP3235499A3 (en) * 2012-03-09 2018-01-17 Lexicon Pharmaceuticals, Inc. Inhibition of adaptor associated kinase 1 for the treatment of pain
AU2013230128B2 (en) 2012-03-09 2017-08-17 Lexicon Pharmaceuticals, Inc. Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶1之抑制劑、包含其之組成物、及其使用方法

Also Published As

Publication number Publication date
DK2834243T3 (en) 2018-07-23
IL234486A (en) 2016-10-31
KR101965025B1 (ko) 2019-04-02
RU2014140735A (ru) 2016-04-27
CN104302649A (zh) 2015-01-21
CN104302649B (zh) 2017-06-23
MX345830B (es) 2017-02-17
BR112014022000A2 (pt) 2017-06-20
KR20140138864A (ko) 2014-12-04
PL2834243T3 (pl) 2018-09-28
EP2834243A1 (en) 2015-02-11
UY34668A (es) 2013-10-31
US8946415B2 (en) 2015-02-03
US20170129896A1 (en) 2017-05-11
EP2834243B1 (en) 2018-04-25
HK1201257A1 (en) 2015-08-28
TR201808280T4 (tr) 2018-07-23
US9403832B2 (en) 2016-08-02
CA2866143A1 (en) 2013-09-12
AU2013230128A1 (en) 2014-09-25
MX381849B (es) 2025-03-13
US20130253194A1 (en) 2013-09-26
ES2676224T3 (es) 2018-07-17
US20150183792A1 (en) 2015-07-02
SG11201405561RA (en) 2014-10-30
TW201341386A (zh) 2013-10-16
JP6418950B2 (ja) 2018-11-07
WO2013134228A1 (en) 2013-09-12
HUE038786T2 (hu) 2018-11-28
NZ630721A (en) 2016-12-23
AU2013230128B2 (en) 2017-08-17
ZA201406149B (en) 2016-06-29
JP2015509535A (ja) 2015-03-30
AR090292A1 (es) 2014-11-05
MX2014010589A (es) 2014-09-18
PT2834243T (pt) 2018-08-01
CA2866143C (en) 2020-08-04
BR112014022000A8 (pt) 2021-06-15

Similar Documents

Publication Publication Date Title
IN2014DN07384A (h)
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
PH12013501758A1 (en) Pyrazolo [1,5-a] pyridines as trk inhibitors
NZ626937A (en) Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
PH12015500988B1 (en) Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
CA2871471C (en) Dna-pk inhibitors
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
LT3808749T (lt) Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai vėžinių susirgimų gydymui
WO2014152029A3 (en) Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
MX2016003456A (es) Compuestos aminopirimidina sustituidos y metodos de uso.
TN2013000325A1 (en) (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases
HK1214823A1 (zh) 作為jak抑制劑的三環稠合噻吩衍生物
HK1213888A1 (zh) 治療化合物和組合物以及其作為pkm2調節劑的用途
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
NZ624063A (en) Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors
NZ629499A (en) Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
MD20150023A2 (ro) Piridinone biciclice noi
HK1216425A1 (zh) 基於2,3-二氢咪唑并[1,2-c]嘧啶-5(1h)-酮的脂蛋白相关磷脂酶a2(lp-pla2)抑制剂
MX340574B (es) Imidazo pirazinas.
NZ630170A (en) Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
UA111520C2 (uk) [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази